204255-04-9

Basic information

• Product Name: N-Desacetyl 5-Azido Oseltamivir
• Synonyms: N-Desacetyl 5-Azido Oseltamivir;(3R,4R,5S)-4-AMino-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic Acid Ethyl Ester;Ethyl (3R,4R,5S)-4-AMino-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
• CAS NO: 204255-04-9
• Molecular Formula: C₁₄H₂₄N₄O₃
• Molecular Weight: 296.36536
• Product Categories: Amines;Intermediates & Fine Chemicals;Pharmaceuticals;Amines, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 204255-04-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: -20?C Freezer
• Solubility: Chloroform, Ethyl Acetate
• CAS DataBase Reference: N-Desacetyl 5-Azido Oseltamivir(CAS DataBase Reference)
• NIST Chemistry Reference: N-Desacetyl 5-Azido Oseltamivir(204255-04-9)
• EPA Substance Registry System: N-Desacetyl 5-Azido Oseltamivir(204255-04-9)

Safety Data

• Hazardous Substances Data: 204255-04-9(Hazardous Substances Data)

Usage

Chemical Properties

Brown Oil

Uses

Intermediate in the production of Oseltamivir. It is a COVID19-related research product.

Upstream product

• 1401454-86-1 tert-butyl (2S,3S)-2-ethenyl-3-{(1R)-3-(ethoxycarbonyl)-1-[(methylsulfonyl)oxy]but-3-en-1-yl}aziridine-1-carboxylate 
• 1401454-87-2 ethyl (1S,5R,6S)-7-(tert-butoxycarbonyl)-5-(methanesulfonyloxy)-7-azabicyclo[4.1.0]hept-2-ene-3-carboxylate 
• 1401454-88-3 ethyl (3R,4S,5R)-4-(tert-butoxycarbonylamino)-3-(1-ethylpropoxy)-5-(methanesulfonyloxy)cyclohex-1-ene-1-carboxylate 
• 1163128-59-3 ethyl (3R,4R,5S)-5-azido-4-[(tert-butoxycarbonyl)amino]-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylate 
• 32384-42-2 (1S,3R,4S,5R)-3,4-O-isopropylidene-1,5-quinic lactone 
• 77-76-9 2,2-dimethoxy-propane 
• 77-95-2 D-(-)-quinic acid 
• 204254-81-9 ethyl (3aR,5S,7R,7aR)-5-hydroxy-7-methanesulfonyloxy-2,2-dimethylhexahydrobenzo[1,3]dioxole-5-carboxylate 
• 204254-98-8 ethyl-(3R,4S,5R)-5-azido-4-hydroxy-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate 
• 1132660-00-4 (3R,4R,5S)-5-azido-4-(diethoxy-phosphorylamino)-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester 
• 204254-90-0 ethyl (3aR,7R,7aR)-2,2-dimethyl-7-methanesulfonyloxy-3a,6,7,7a-tetrahydrobenzo[1,3]dioxole-5-carboxylate 
• 204254-84-2 ethyl (3aR,7R,7aR)-2,2-dimethyl-7-methanesulfonyloxy-3a,6,7,7a-tetrahydrobenzo[1,3]dioxole-5-carboxylate 
• 204254-96-6 (1S,5R,6S)-5-(pentan-3-yloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylic acid ethyl ester 
• 204255-02-7 ethyl-(1R,5R,6R)-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate 

Downstream Products

• 204255-06-1 oseltamivir 
• 204255-11-8 oseltamivir phosphate 
• 187227-45-8 oseltamivir acid 
• 196618-13-0 oseltamivir 
• 367252-68-4 (3R,4R,5S)-ethyl 4-acetamido-5-((tert-butoxycarbonyl)amino)-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate 
• 208589-23-5 (3R,4R,5S,6R)-4-Acetylamino-5-tert-butoxycarbonylamino-3-(1-ethyl-propoxy)-6-methyl-cyclohex-1-enecarboxylic acid ethyl ester 
• 208589-20-2 (1S,2R,3S,4R,5S)-4-Acetylamino-5-tert-butoxycarbonylamino-3-(1-ethyl-propoxy)-1,2-dihydroxy-cyclohexanecarboxylic acid ethyl ester 
• 208589-21-3 (3S,4R,5S,6S)-4-Acetylamino-3-tert-butoxycarbonylamino-5-(1-ethyl-propoxy)-6-hydroxy-cyclohex-1-enecarboxylic acid ethyl ester 
• 208589-22-4 (3S,4R,5S,6S)-6-Acetoxy-4-acetylamino-3-tert-butoxycarbonylamino-5-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester 
• 1362750-72-8 C₁₈H₂₈N₄O₄ 
• 1362750-86-4 C₁₇H₂₆N₄O₄ 
• 1362750-75-1 C₂₁H₃₇N₂O₄P 
• 1362750-78-4 C₁₈H₃₀N₂O₄ 
• 1362750-47-7 PMC-33 

Relevant articles and documents

Synthesis and characterization of potential pharmacopeial impurities of oseltamivir: An antiviral drug

Impurities of oseltamivir phosphate were synthesized from chiral epoxide (1) in a simpler and much feasible synthetic approach in seven steps accounting to 8.2 % overall yield. The nucleophilic addition of N3 (highly regioselective and stereoselective) in

METHOD FOR PREVENTING OR TREATING ARRHYTHMIA, METHOD FOR PREVENTING OR TREATING ATRIAL FIBRILLATION, MODEL OF SUSTAINED ATRIAL FIBRILLATION, METHOD FOR PRODUCING THE MODEL, AND METHOD FOR SCREENING FOR ATRIAL FIBRILLATION INHIBITOR

A method for preventing or treating atrial fibrillation, including: administering, to an individual, an atrial fibrillation inhibitor containing a compound expressed by one of the following Structural Formulas (I) to (VI) or a pharmacologically acceptable salt thereof: where in the Structural Formula (III), Gluc refers to glucuronic acid,

Preparation of oseltamivir phosphate

The invention provides a new process for the conversion of shikimic acid to oseltamivir (I), and optionally to an acid addition salt, via the intermediate phosphoramide VII.